Xeris Biopharma Holdings, Inc. (XERS) Deferred Tax Assets, Valuation Allowance USD 2019 - 2023

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Xeris Biopharma Holdings, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from 2019 to 2023.
  • Xeris Biopharma Holdings, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $173 M, a 8.94% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $173 M +$14.2 M +8.94% Dec 31, 2023 10-K 2024-03-06
Q4 2022 $159 M +$21.2 M +15.3% Dec 31, 2022 10-K 2024-03-06
Q4 2021 $138 M +$45.4 M +49.1% Dec 31, 2021 10-K 2024-03-06
Q4 2020 $92.5 M +$23.5 M +34.1% Dec 31, 2020 10-K 2024-03-06
Q4 2019 $69 M Dec 31, 2019 10-K 2022-03-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.